B8F Stock Overview
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biofrontera AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.45 |
| 52 Week High | €1.60 |
| 52 Week Low | €0.45 |
| Beta | 0.90 |
| 1 Month Change | -14.91% |
| 3 Month Change | -18.88% |
| 1 Year Change | -71.72% |
| 3 Year Change | -85.16% |
| 5 Year Change | -91.95% |
| Change since IPO | -97.06% |
Recent News & Updates
Shareholder Returns
| B8F | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.4% | -2.2% | 1.4% |
| 1Y | -71.7% | -23.7% | 2.5% |
Return vs Industry: B8F underperformed the German Pharmaceuticals industry which returned -23.7% over the past year.
Return vs Market: B8F underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| B8F volatility | |
|---|---|
| B8F Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.3% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: B8F is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: B8F's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 92 | n/a | https://www.biofrontera.com |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin.
Biofrontera AG Fundamentals Summary
| B8F fundamental statistics | |
|---|---|
| Market Cap | €28.78m |
| Earnings (TTM) | -€8.60m |
| Revenue (TTM) | €28.63m |
1.0x
P/S Ratio-3.3x
P/E RatioIs B8F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B8F income statement (TTM) | |
|---|---|
| Revenue | €28.63m |
| Cost of Revenue | €5.71m |
| Gross Profit | €22.92m |
| Other Expenses | €31.53m |
| Earnings | -€8.60m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 80.07% |
| Net Profit Margin | -30.06% |
| Debt/Equity Ratio | 0.3% |
How did B8F perform over the long term?
See historical performance and comparison